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Dear Sir: 
We have read with great interest a recent article by Dr. He et al. in the June issue of 
Gastroenterology.
1
 The studies provide strong evidence in favor of the concept that smooth 
muscle–specific myosin phosphatase target subunit 1 (MYPT1) of myosin light chain 
phosphatase (MLCP) plays a critical role in the agonist-induced contraction/relaxation of the 
smooth muscle.  This was shown in their studies using animals with knocked out MYPT1
-/-
.  The 
investigators employed the Cre-loxP system in which they used the promoter region and exon 1 
of Mypt1 flanked by 2 loxP sites to establish Mypt1-floxed mice.  These mice were crossed with 
SMA-Cre transgenic mice to generate smooth muscle–specific MYPT1 knockout mice 
(Mypt1
SMKO
). 
The authors demonstrated that the phasic responses (to acetylcholine, ACh and K
+
-
depolarization) of the jejunal and ileal smooth muscles of the mutant mice in comparison with 
the control mice are converted into a tonic type with sustained force.  The converted responses 
had reduced rates of shortening velocity and relaxation because of higher levels of phospho-
MLC20 (p-MLC20).  The authors observed no apparent abnormality in the intestinal motility in 
the mutant mice, although there was a definite trend towards the decrease in the intestinal transit 
(a predicted effect).  The lack of statistical significance for the abnormal intestinal motility may 
have been because of the huge variability among the mutant mice reflected by 49.9 ± 13.9 SEM 
% transit values.  The issue of intestinal motility abnormality in the Mypt1
SMKO
 may be resolved 
by studying a larger number of animals with a group beyond 16-week old, and by detailed 
examinations of the entire gut from the esophagus to the anorectum.  The present studies had 
primarily focused on the limited regions of the gastrointestinal tract.  
Critical role of MYPT1 in the sustained contraction has been previously demonstrated in the 
phenotypically tonic vs. the phasic smooth muscles of the gastrointestinal tract, in the basal 
state.
2,3
  Additionally, there appear to be certain similarities between Mypt1
SMKO
 animals and the 
spontaneously hypertensive rats: an increase in blood pressure and in the intestinal smooth 
muscle contractility with a corresponding decrease in MYPT1.
1,4,5
  An increase in the 
neurotransmitter (ACh)-mediated amplitude and sustained contraction of the intestinal smooth 
muscle in MYPT1
SMKO
 is suggestive of dysfunctional smooth muscle typified in the diffuse 
esophageal spasm in response to swallowing.  It has been proposed that defective inhibitory 
neurotransmission mediated by nitric oxide (NO) and vasoactive intestinal polypeptide (VIP), 
unopposed excitatory neurotransmitters’ (ACh; substance P, SP) contractile actions, and 
increased smooth muscle sensitivity may be responsible for the uncoordinated often hypertensive 
contractions, failure of the descending inhibition, and achalasic/hypertensive sphincteric smooth 
muscles.
6
 
Present data with the higher sensitivity of the smooth muscle in response to the excitatory 
agonists in the presence of similar concentrations of intracellular Ca
2+
, suggest the role of Ca
2+-
sensitization via inhibition of MLCP via MYPT1, the primary target for RhoA/ROCK.  Also, 
there are studies to show significantly higher levels of endogenous inhibitory protein CPI-17 
(originally named so because of its targeting PKC, protein-kinase C potentiated inhibitor) in the 
tonic vs. phasic smooth muscles.  Recently, it is becoming evident that RhoA/ROCK contributes 
to Ca
2+
 sensitization not only by targeting MYPT1 but also by targeting CPI-17, so that CPI-17 
is not exclusively targeted by PKC.
3,7
  Data from humans and animals show significantly higher 
levels of CPI-17 in the spontaneously tonic smooth muscle vs. the phasic, and specific decreases 
in the phospho-CPI-17 following selective RhoA/ROCK inhibitors.  The bimodal effect of 
RhoA/ROCK on MYPT1 and CPI-17 however was not appropriately discussed in the paper by 
He et al. 
In view of a critical role of MLCK/MYPT1-MLCP/p-MLC20 in the smooth muscle 
relaxation/contraction, it is important to determine the significance of MYPT1 in the region-
specific pathophysiology in response to the corresponding reflexes, e.g. swallowing in the case 
of esophagus, and rectoanal inhibitory (defecation) reflex in the anorectum.  In this regard, the 
potential of MYPT1 gene-deleted animal models similar to that of Mypt1
SMKO
 (but without 
compensatory genetic and adaptive physiologic responses) may go beyond the investigation of 
the molecular mechanisms for the agonist-induced smooth muscle contraction.  Such molecular 
insights may further reveal the pathophysiology of certain motility disorders, with or without 
characteristic dysfunctional inhibitory and excitatory neurotransmissions as discussed before.
6
  
These disorders may involve MYPT1-associated deranged signal transduction cascade for the 
smooth muscle contraction/relaxation to explain disturbed changes in the latency gradient for the 
sequential contractions, a hall mark for the normal progression of the food and ingesta leading to 
the expulsion of the waste.
8
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